Calcitonin gene related peptide receptor

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 20.01.2025

Dieser Artikel auf Deutsch

Synonym(s)

CGRP receptor; OMIM: 114190; Syn CGPCR

Definition
This section has been translated automatically.

The Calcitonin Gene-Related Peptide receptor is a receptor protein found in the membrane of vertebrates that is activated by its ligand, the Calcitonin Gene-Related Peptide (CGRP). The receptor mediates its effects through activation of Gs proteins and subsequent activation of adenylyl cyclases. The coding gene (CALCRL) for the calcitonin receptor-like receptor is located on chromosome 2 in the gene locus q31-q32.

General information
This section has been translated automatically.

All peptides of the calcitonin peptide group act via one of 2 G-protein-coupled receptors (GPCR), the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR).

Heterodimerization of these GPCRs with one of three receptor activity modifying proteins (RAMP) increases. Complex formation of multiple proteins is critical for ligand specificity and function of the receptor. The members of the calcitonin peptide family bind to the different receptors with varying degrees of activity (see figure).

The CGRP receptor consists of a heterodimer with CLR and the receptor activity-modifying protein 1 (RAMP1) (McLatchie et al ). Here, the ligand binding domain is located between RAMP and CLR (Hay et al 2016). The receptor-mediated increase in intracellular cAMP leads to an activation of protein kinase A, whereupon various factors such as ATP-dependent potassium channels, ERKs (extracellular-signal regulated kinases) and transcription factors such as CREB (cAMP response element-binding protein) are phosphorylated. This enables the transcription of target genes, among other things. The CGRP receptor is mainly expressed in the vascular smooth muscle, but also by neurons of the trigeminal ganglion and certain glial cells (Eftekharis et al 2010).

Initial successes have been achieved in rosacea with an anti-CGRP receptor antibody (erenumab).

Clinical picture
This section has been translated automatically.

Migraine: CGPR is believed to play a causal role in the development of migraine (Guo et al. 2017). This is underlined by experimental data and clinical study results obtained with monoclonal antibodies that block CGRP or the CGRP receptor highly selectively.

Literature
This section has been translated automatically.

  1. Eftekharis S et al (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14: 1289-1303
  2. Guo S et al (2017) Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalagia 37: 114-124
  3. Hay DL et al (2016) Receptor activity-modifying proteins (RAMPs): New insight and roles. Annu Rev Pharmacol Toxicol 56: 469-487
  4. Kukowski B (2018) CGRP signal transduction. Aspects of the development of migraine and current drug therapy approaches. https://www.cme point.de/Fortbildungen/2370_CGRP_CME_FINAL.pdf (taken on 1.9.2020)

  5. McLatchie LM et al (1989) RAMPs regulate the transport and ligand specifity of the Calcitonin-receptor-like receptor. Nature 393: 333-339
  6. Russel FA et al (2014) Calcitonin gene-related peptides: physiology and pathophysiology. Physiol Rev 94: 1099-1142

Incoming links (1)

Rosacea papulopustulosa;

Authors

Last updated on: 20.01.2025